(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 16.28% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.81%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.6%.
Cytosorbents's revenue in 2026 is $37,063,000.On average, 5 Wall Street analysts forecast CTSO's revenue for 2026 to be $2,564,241,900, with the lowest CTSO revenue forecast at $2,402,538,600, and the highest CTSO revenue forecast at $2,686,068,000. On average, 4 Wall Street analysts forecast CTSO's revenue for 2027 to be $3,138,950,100, with the lowest CTSO revenue forecast at $2,895,548,700, and the highest CTSO revenue forecast at $3,360,218,400.
In 2028, CTSO is forecast to generate $3,640,612,800 in revenue, with the lowest revenue forecast at $3,170,300,100 and the highest revenue forecast at $4,098,573,600.